Ansys And Schrödinger Collaborate To Develop ICME Approach
$ANSS
$SDGR
Computer Software: Prepackaged Software
Technology
Biotechnology: Pharmaceutical Preparations
Health Care
Ansys And Schrödinger Collaborate To Develop ICME Approach
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 12/15/2025 | $24.00 | Neutral → Buy | BofA Securities | |
| 9/30/2025 | $19.00 | Neutral | Goldman | |
| 8/15/2025 | $20.00 | Buy → Neutral | Citigroup | |
| 8/14/2025 | $25.00 | Overweight | Barclays | |
| 7/14/2025 | Outperform → Neutral | Robert W. Baird | ||
| 7/3/2025 | $28.00 | Equal-Weight | Morgan Stanley | |
| 7/2/2024 | $29.00 | Outperform | Leerink Partners | |
| 12/5/2023 | $38.00 | Overweight | KeyBanc Capital Markets |
10-Q - Schrodinger, Inc. (0001490978) (Filer)
8-K - Schrodinger, Inc. (0001490978) (Filer)
SCHEDULE 13G/A - Schrodinger, Inc. (0001490978) (Subject)
Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER, BC, Jan. 29, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global AI medical imaging market exploded to a staggering $2.57 trillion in 2026 as the entire healthcare ecosystem ditched trial-and-error medicine for AI-native diagnostic precision and autonomous operations[1]. This massive movement has pushed the AI drug discovery sector to $1.81 billion, powered by "federated learning" models that use high-frequency sensing to collapse development timelines from years into months[2]. This new Diagnostic Data Core is creating massive tailwinds for VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Recursion Pharmaceutical
Schrödinger, Inc. (NASDAQ:SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its physics+AI computational platform and serving as a global leader in computational molecular discovery. "In 2025, we witnessed the continued impact of scaling ‘physics+AI' to solve the challenges of data scarcity and to accelerate the discovery of differentiated molecules. We are entering 2026 with a clear mandate: to further strengthen our position as the essential design engine for the industry," stated Ramy Farid, Ph.D., chief executive officer at Schrödinger. "Our priorities for 2026 are focus
Schrödinger, Inc. (NASDAQ:SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger's widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows. "As a leader in computational drug discovery, Schrödinger is pleased to partner with Lilly TuneLab," stated Pat Lorton, chief technology officer and chief operating officer, software at Schrödinger. "We are pleased that LiveDesign will
4 - Schrodinger, Inc. (0001490978) (Issuer)
4/A - ANSYS INC (0001013462) (Issuer)
4/A - ANSYS INC (0001013462) (Issuer)
BofA Securities upgraded Schrodinger from Neutral to Buy and set a new price target of $24.00
Goldman initiated coverage of Schrodinger with a rating of Neutral and set a new price target of $19.00
Citigroup downgraded Schrodinger from Buy to Neutral and set a new price target of $20.00
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Thomson Reuters Corp (NASDAQ:TRI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX®) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 28, 2025. Thomson Reuters Corp will replace ANSYS, Inc. (NASDAQ:ANSS) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. ANSYS, Inc. will also be removed from the Nasdaq-100 Tech Sector™ Index (NASDAQ:NDXT), the Nasdaq-100 Technology Sector Market-Cap Weighted™ Index (NDXTMC™), the Nasdaq-100 Technology Sector Adjusted Market-Cap Weighted™ Index (NDXT10™), the Nasdaq-100 ESG™ Index (NASDAQ:ND
NEW YORK, July 14, 2025 /PRNewswire/ -- The Trade Desk Inc. (NASD: TTD) will replace ANSYS Inc. (NASD: ANSS) in the S&P 500 effective prior to the opening of trading on Friday, July 18. S&P 500 constituent Synopsys Inc. (NASD: SNPS) will acquire ANSYS in a deal expected to be completed on July 17. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 18, 2025 S&P 500 Addition The Trade Desk TTD Communication Services July 18, 2025 S&P 500 Deletion ANSYS ANSS Information Technology For more information about S&P Dow Jones Indices, please visit www.spdji.com ABOUT S&
Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w
Third Quarter Total Revenue of $54.3 Million, Software Revenue of $40.9 Million Updates 2025 Financial Guidance Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended September 30, 2025. "Schrödinger delivered a solid third quarter with software revenue growth of 28%, reflecting the industry's increasing demand for our leading computational platform," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "While we are encouraged by the continued high level of customer engagement as the macroeconomic pressures that have affected the industry stabilize, we have lowered our software revenue growth guidance by two percent to 8% to 13%. This updated
Schrödinger (NASDAQ:SDGR) will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharm
Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended June 30, 2025. "In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven c
SC 13G - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)
SC 13G/A - ANSYS INC (0001013462) (Subject)